Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics
of PRX-03140 administered orally once daily for 14 days in subjects with mild Alzheimer's
Disease who are using a stable, well-tolerated 10 mg dose of Aricept (donepezil) but continue
to experience worsening AD symptoms.